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Abstract The microtubule-associated protein tau in human 
brain consists of six molecular isoforms derived from a single 
gene by alternative mRNA-splicing and further modified by 
posttranslational processing. In the present study, the distribution 
of tau isoforms in grey and white matter of human temporal 
cortex was investigated by two-dimensional gelelectrophoresis. 
More than 80 isoforms were detected. The pattern of isoforms 
obtained after treatment with alkaline phosphatase was still more 
complex than those of recombinant tau, indicating that posttrans- 
lational modifications other than phosphorylation contribute to 
the molecular heterogeneity of tau. The tau isoform D according 
to Goedert [I] containing four tubulin-binding regions shown to 
promote tubulin polymerisation most efficiently was present in 
higher amounts in white as compared to grey matter. The pattern 
of isoform distribution was not significantly altered in Alz- 
heimer's disease. It is concluded that molecular isoforms that 
differ in their tubulin-binding characteristics are differentially 
distributed in subceliular neuronal compartments and/or neuronal 
types. 
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I. Introduction 
Tau is a cytoskeletal protein that regulates tability and dy- 
namics of microtubule by direct interaction with tubulin. In the 
adult human brain, six different au isoforms are generated by 
alternative mRNA-splicing. These isoforms differ by the pres- 
ence of either three or four copies of a highly conserved 18- 
amino acid repeat separated from one another by 13-14-amino 
acid inter-repeat domains in the carboxy terminus and the in- 
sertion of one or two N-terminal 29-amino acid motifs [1]. The 
N-terminal inserts largely consist of acidic amino acid residues, 
while the carboxyl terminus which possesses tubulin-binding 
activity has a strong basic bias [2]. Isoforms with three tubulin- 
binding motifs containing either none, one or two N-terminal 
inserts are designated according to the nomenclature of Goe- 
dert [1] as A, B and C, respectively. The corresponding isoforms 
with four tubulin-binding motifs are referred to as D, E and F 
[1,3]. 
The binding of tau to microtubules i  physiologically modu- 
lated by its phosphorylation state [4,5]. Highly phosphorylated 
tau species, such as those present in paired helical filaments 
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(PHFs), one of the major molecular hallmarks of Alzheimer's 
disease (AD), are largely prevented from the efficiently binding 
microtubules [6,7]. The pathological phosphorylation state of 
tau under this condition is, therefore, believed to lead to an 
impaired microtubular organisation and eventually to a pathol- 
ogically disturbed axonal transport [8]. 
On the longest human tau isoform, 19 potential in vivo phos- 
phorylation sites have up to now been identified. Most of them 
are serine or threonine residues, followed by proline [9]. This 
phosphorylation f tau is probably the most important modifi- 
cation of tau which contributes to its molecular heterogeneity. 
As phospho-isoforms of tau differ with respect o both electro- 
phoretic mobility and pI, they can be separated on SDS-PAGE 
and by isoelectric focusing [4]. By 2D gel analysis as many as 
60 different isoforms have been detected in adult mouse brain 
[10]. In the present study, the distribution of molecular isoforms 
and the contribution of phosphorylation to their molecular 
heterogeneity was studied in the soluble tau fraction of grey and 
white matter of temporal cortex. Brains from controls and 
patients with AD were analysed. 
2. Materials and methods 
2.1. Brain tissue 
Post-mortem human brain tissues from the temporal cortex 
(Brodmann area 22) of five normal brains (controls) and six brains 
affected by AD [11,12] were investigated in the present study. Age 
(control: 72.6 + 16.6; AD: 84.3 + 5.8 years), premortem severity index 
(control: 2.3 + 0.8; AD: 2.4 + 0.9) [13] and postmortem delay (control: 
54.5 + 15.8 h; AD: 59.1 + 29.3 h) did not significantly differ between 
controls and cases of AD (Student's t-test, P > 0.1). Severity of AD 
assessed according to the Reisberg scale [14] ranged from GDS 2 to 7. 
2.2. Preparation of soluble tau-protein 
White and grey matter of the temporal cortex was carefully dissected 
and homogenised in 3 volumes of ice-cold MES buffer [0.1 M 2(N- 
morpholino)ethanesulfonic acid, pH 6.5, 1 M NaC1, 0.5 mM MgCI2, 
2 #l/ml Triton X-100, 1 mM EGTA, 1 mM EDTA, 1 mM NaF, 1 mM 
phenylmethylsulfonyl fluoride, 1 #g/ml pepstatin, 1#g/ml eupeptin, 
1 #g/ml N-p-tosyl-L-lysine chloromethyl ketone, 1#g/ml aprotinin]. The 
100,000 x g supernatant (30 min, 4°C) was supplemented with 2-mer- 
captoethanol to a final concentration f 5 #l/ml and boiled for 5 min. 
After centrifugation (50,000 x g, 20 rain, 4°C), the supernatant was 
adjusted to 25 #l/ml HC104 and incubated on ice for 15 min. After 
another centrifugation (50,000 x g, 20 min, 4°C), the supernatant was 
precipitated with 60 mg/ml trichloroacetic a id for 20 min on ice. The 
pellet (50,000 x g, 20 min, 4°C) containing enriched tau-protein was 
washed twice with ice-cold methanol. Protein content was determined 
in 96-well polystyrene microtiter plates according to Lowry et al. [15]. 
2.3. Treatment with alkaline phosphatase 
Tau protein was dissolved to a final concentration f 2 mg protein/ml 
in phosphatase buffer (0.1 M Tris-HC1, pH 8.4, 0.15 M NaC1, 2 mM 
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ZnC12, MgC12, 4 mM phenylmethylsulfonyl fluoride, 10/zg/ml pep- 
statin, 10/tg/ml eupeptin, 10/tg/ml N-p-tosyl-L-lysine chloromethyl 
ketone, 10 /.tg/ml aprotinin). 18 U/ml bacterial orthophosphoric- 
monoester phosphohydrolase from E. coli, alkaline optimum Type III- 
S (alkaline phosphatase, EC 3.1.3.1.; Sigma) were added and samples 
were incubated for 1, 2, 4 or 8 h at 67°C. Control incubations were 
performed in the presence of 0.2 M sodium pyrophosphate. Incubation 
was stopped by adding 0.2 mg/ml ice-cold trichloroacetic a id (20 min), 
precipitated protein was pelleted (50,000 x g, 20 min, 4°C) and washed 
twice with ice-cold methanol. 
2.4. Electrophoretic separation of tau isoforms 
Two-dimensional gel electrophoresis was used for separation of sin- 
gle tau-isoforms. Separation in the first dimension was performed as 
non-equilibrium pH-gradient electrophoresis (NEPHGE) according to 
O'Farrell et al. [16]. 1 mm tube gels containing 37.84 mg/ml acrylamide, 
2.16 mg/ml N,N'-methylene bisacrylamide (Bis) (4% T, 5.4% C), 9.2 M 
urea, 5/tl/ml Triton X-100 and 40/-tl/ml Pharmalyte 3-10 (Pharmacia) 
were cast to a length of 60 ram. Samples were dissolved to a final 
concentration of 1/lg//A protein in 9.5 M urea, 5/A/ml Triton X-100, 
20/tl/ml Pharmalyte 3-10 (Pharmacia), 10 mM dithiothreitol (DTT). 
The tubes were loaded at the anode with 30/zl sample, overlaid with 
3 M urea, 3.3/A/ml Pharmalyte (Pharmacia) and run in a Mini-Protean 
II tube cell (BioRad) with 2.5 mM H3PO4 for the anode compartment 
and 50 mM L-lysine solution for the cathode compartment. The electric 
current was regulated as follows: 15 min at 300 V, 15 rain at 500 V and 
90 min at 750 V at 10-12°C. Gels were ejected from the tubes and 
incubated for 10 rain in 62.5 mM Tris-HC1 buffer, pH 6.8, containing 
100/A/ml glycerol, 20/zg/ml sodium dodecyl sulfate (SDS) and 50/zl/ml 
2-mercaptoethanol. After incubation the gels were either stored at 
-20°C or directly used for separating the proteins in the second imen- 
sion. 
Sodium dodecyl sulfate polyacrylamide lectrophoresis (SDS- 
PAGE) was performed according to Laemmli [17], either on Minigels 
(Mini-Protean II; BioRad) or on 160 × 200 mm vertical gels (Protean 
IIxi; BioRad), containing 97.3 mg/ml acrylamide and 2.7 mg/ml Bis 
(10% T, 2.7% C), 375 mM Tris-HC1, pH 8.8 and 1 mg/ml SDS. One or 
two NEPHGE gels were loaded on Minigels or large slab gels. Molec- 
ular weight standards and tau probes for control incubation on Western 
blots were loaded into extra slots. 
Optimal 2D-resolution of tau was obtained with 4% (w/v) pH 3-10 
ampholyte gels. Ampholytes with a more basic pH range prevented the 
most acidic isoforms from migrating into the gel, whereas amore acidic 
ampholyte composition caused an exclusion of the basic isoforms. 
Moreover, resolution in NEPHGE was temperature-dependent. Op i- 
mal resolution was obtained at 10-12 °C. Higher temperatures resulted 
in stretching the pH-gradient while lower temperatures compressed the 
banding pattern. For designation of isoforms derived by alternative 
mRNA splicing the nomenclature given by Goedert [1] was used. 
Total soluble proteins were extracted from brain tissue, separated in
large 2D-gels (first dimension 400 mm, second imension 300 mm) and 
detected by silver staining using the methods described by Klose and 
Kobalz [18]. 
2.5. Western blotting 
Proteins, separated on one- or two-dimensional gels were transferred 
onto Polyscreen PVDF transfer membranes (DuPont) using a water- 
cooled tank blot transfer cell (Trans-blot cell; BioRad; 50 V 3 h). The 
blot buffer contained 48 mM Tris, 39 mM glycine, 0.13 mM SDS and 
200/A/ml methanol [19]. Marker strips were stained with 1 mg/ml 
Coomassie brilliant blue in 100 #l/ml acetic acid, 500/A/ml methanol) 
and destained twice with 100/,tliml acetic acid, 500 ,ul/ml methanol. 
Irnmunoblots were blocked with 10 mg/ml gelatine for 1 h. After two 
washing steps in phosphate-buffered saline (PBS: 10 mM Na2HPO4/ 
NaH2PO4, pH 7.4, 150 mM NaC1) containing 1/ll/ml Tween 20, blots 
were incubated for 1 h in the presence of one of the following primary 
antibodies, diluted in PBS, containing 0.5/A/ml Tween 20: monoclonal 
antibodies (mab) anti-tau 1 (Boehringer Mannheim; 1: 10,000), mab 
HT 7 (Innogenetics; 1 : 4,000), mab AT 8 (Innogenetics; 1 : 4000) and the 
polyclonal antibody BR 134 (courtesy of M. Goedert; 1:2000). Blots 
were washed twice (5 min) and incubated with the biotinylated sheep 
anti-mouse antibody (Amersham; 1 : 2000; 50 min) or biotinylated don- 
key anti-rabbit antibody (Amersham; 1: 1000; 1 h) for primary mono- 
clonal and polyclonal antibodies, respectively. Following two washing 
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Fig. 1. High-speed supernatant ofhuman brain tissue resolved in a large 
gel (300 × 400 mm) by 2D electrophoresis. (A) Silver staining; (B) West- 
ern blot probed with mab HT 7. Corresponding dots are marked by 
arrowheads. 
steps (5 min), immunoreactivity was visualised by an avidin-peroxidase 
complex (ExtrAvidin; Sigma; 1: 1000) and 3,Ydiaminobenzidine/NiCl2. 
For quantification oftau protein, blots were incubated with mab HT 
7 (Innogenetics; 1:2000; 1 h), washed three times (10 min) and probed 
with ~25I-labelled sheep anti-mouse antibody (Amersham; 1:400;1 h). 
Following three washing steps (10 min), immunoreactivity was visual- 
ised by a peroxidase-labelled rabbit anti-sheep antibody (1:1000; 
Dako) and 3,3'diaminobenzidine/NiC12. 
2.6. Quantification of tau on immunoblots 
Blotting membranes were probed with mab HT 7 and [~zSI]anti- 
mouse antibody/peroxidase-labelled anti-sheep antibody. Spot groups, 
derived from one isoform, were cut out and quantified with a gamma- 
counter (multi crystal gamma counter LB 2104; Bertold). The activity 
(cpm) of each of the six isoforms was expressed as percentage of the 
total of all six isoforms. 
Quantification was performed within the range of linearity between 
radioactivity (cpm) and the amount of tau protein blotted onto the 
membranes. 
3. Results 
3.1. Identification of  tau isoforms 
The protein tau identified in 2D-electrophoresis patterns of 
the soluble proteins of human brain tissue displayed a complex 
pattern consisting of more than 80 single spots at a pI range 
between approximately 6.1 and 8.0 (Fig. 1). In order to distin- 
guish between molecular isoforms derived by alternative 
mRNA splicing and post-translational modifications, the tau 
pattern obtained from brain tissue was compared with that 
of human recombinant tau, expressed in E. coli (courtesy of 
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Fig. 2. Comparative analysis of Western blots of human soluble tau and 
recombinant tau, separated by one-dimensional SDS-PAGE (A) and 
2D electrophoresis using NEPHGE for the separation i the first di- 
mension (B). Lanes 1, 5 and 6: soluble human tau prepared from brain 
tissue, lanes 2, 4 and 7: soluble human tau treated with alkaline phos- 
phatase (4 h) and lanes 3 and 8: recombinant human tau. Lanes 1 to 
3 and 6 to 8 were probed with mab HT 7, lanes 4 and 5 with the 
polyclonal ntibody BR 134. 
M. Goedert, Cambridge). The complex pattern of freshly pre- 
pared tau was reduced by treatment with alkaline phosphate to 
an SDS-PAGE banding pattern that aligns with the six bands 
of recombinant tau (Fig. 2A). Both freshly prepared tau and 
tau treated with alkaline phosphatase howed additional bands 
at a molecular weight range below the smallest recombinant tau 
isoform. These low molecular weight bands react with the mabs 
anti-tau 1and HT 7 but fail to stain with the antibody BR 134 
which specifically recognises the C-terminus of tau (Fig. 2A). 
Thus, they are likely to represent proteolytic degradation prod- 
ucts. The 2D pattern of tau protein obtained after phosphatase 
incubations inthe presence of 0.2 M pyrophosphate was similar 
to that of the untreated material. 
By 2D electrophoresis, the mixture of the six human recom- 
binant au isoforms (courtesy of M. Goedert, Cambridge) was 
resolved into a pattern of six spots (Fig. 2B, sample 8), each 
representing a tau-isoform derived from a different mRNA. 
Migration properties of the recombinant proteins in 2D elec- 
trophoresis were related to charge and molecular weight of the 
inserts which correspond to the alternatively spliced exons in 
the sequence of tau [2]. Isoforms containing four tubulin-bind- 
ing regions migrated closer towards the alkaline site compared 
to their molecular counterparts with only three tubulin-binding 
regions (compare D/A, E/B, F/C). While this finding matches 
the basic bias of the additional tubulin-binding domain, the 
acidic bias of the alternatively spliced N-terminal inserts led to 
an increase in acidity of the isoforms containing these region(s). 
In the pH-gradient of the 2D pattern, isoforms, containing the 
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Fig. 3. Synopsis of the pattern of human molecular tau-isoforms identified after two-dimensional separation. Spots, belonging to the same molecular 
isoform are drawn with the same shade of grey. The diagram above shows the exon pattern of the different splicing products of human tau which 
lead to the molecular heterogeneity of the protein (after Goedert, 1993 [1]). 
(1) The six recombinant isoforms of human tau, separated by SDS-PAGE. The isoforms, ymbolised inthis drawing, are in a non-phosphorylated 
form (classification f isoforms according to Goedert, 1993 [1]). 
(2) The six recombinant isoforms, resolved by two-dimensional gel electrophoresis. Each spot was assigned to a single isoform by alignment with 
the SDS-PAGE bands (compare 1). 
(3) 2D pattern ofa dephosphorylatedpreparation of human tau. This pattern is similar to the pattern of the recombinant isoforms (compare 2). 
(4) 2D pattern of human tau. Compared to the pattern of dephosphorylated human tau, this pattern contains pot groups that differ in apparent 
molecular weight from the proteins that were present in the 2D pattern of recombinant and dephosphorylated au(compare 2,3). Those additional 
bands were identified as phosphoisoforms of tau, because they disappeared after dephosphorylation. The way in which the pattern of human tau 
is hypothesised to be changed by dephosphorylation (compare 3) is indicated by black arrows. 
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same number of tubulin-binding regions differ in their acidity 
due to their number of N-terminal inserts (compare A/B/C and 
D/E/F). 
By comparison, freshly prepared tau showed additional spots 
which differed from the pattern of recombinant tau with respect 
to both pI and mobility on SDS-PAGE (Fig. 2B, sample 6). 
After phosphatase treatment, the pattern of tau prepared from 
human postmortem brain was still more complex than that of 
recombinants (Fig. 2B, sample 7). However, only those spots 
remained which comigrated with the SDS-bands of recombi- 
nants but still varied in their pI. Each phosphatase-resistant 
band had two corresponding phosphatase-sensitive copies, 
which were shifted towards the acidic end of the NEPHGE gel 
and decreased in SDS mobility. SDS-PAGE mobility shift and 
acidic shift of these additional bands were interrelated. The 
principal findings of the 2D analysis of human soluble tau 
relating it to the pattern of recombinant tau are summarised in
Fig. 3. 
3.2. Quantification of  tau &oforms 
Preparations of soluble tau, obtained from either white or 
grey matter of controls and of cases with AD were resolved in 
2D gels and quantified after radioactive labelling. The two 
isoforms characterised by two N-terminal inserts (isoforms C 
and F according to Goedert [1]) could hardly be discriminated 
by 2D separation and were thus analysed together (Fig. 4). 
In the normal human brain, significant differences between 
the distribution of isoforms in grey and white matter were 
observed (Figs. 4, 5). In grey matter, the isoform B (i.e. the 
isoform containing three tubulin-binding regions and one N- 
terminal insert) was most prominent while in white matter, 
isoform D (i.e. the isoform containing four tubulin-binding 
regions and no N-terminal insert) and B, present in about equal 
amounts, were the most abundant isoforms, but without reach- 
ing the level of B in the grey matter. The content of isoform D 
in white matter was about twice as high as in grey matter. 
Isoforms C and F were least abundant in both grey and white 
matter. No significant changes of the overall pattern of 
isoforms were observed in AD (Fig. 5). 
r.,._ 6) 
1 2 
Fig. 4. Two-dimensional Western blot of soluble tau protein prepared 
from grey (1) and white matter (2) of normal human brain used for 
quantification f single isoforms. Equal amounts of purified tau were 
first run in NEPHGE, followed by separation i a 160 × 200 mm SDS- 
gel. The mab HT 7 was used as primary antibody. Note the differences 
in the relative amount of isoform D spots (arrowheads). 
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Fig. 5. Relative distribution of tau isoforms in grey and white matter 
of normal human brain and in AD. Data are mean (n = 5 controls and 
n = 6 AD cases) expressed asa percentage of total tau content (relative 
isoform content = cpm(isoform)/cpm(~,isoforms A-F) × 100%). Error 
bars indicate the data S.E.M. Isoforms were designated according to 
the nomenclature of Goedert [1] (see Fig. 3). Differences between grey 
and white matter were significant for: *P = 0.016, **P = 0.008 and 
***P = 0.004 (Mann-Whitney U-test [37]). 
4. Discussion 
In the present study, the distribution of molecular isoforms 
of the microtubule-associated protein tau was investigated in
the human temporal cortex by 2D-gel electrophoresis. A com- 
plex pattern of more than 80 distinct isoforms was resolved. 
The molecular heterogeneity of tau is due to both mRNA- 
processing as well as posttranslational processing [4]. 
For each single isoform derived by alternative mRNA-splic- 
ing a single spot or a closely related group of spots with similar 
SDS-PAGE migration properties were resolved from a mixture 
of the recombinant human isoforms and dephosphorylated 
human tau, respectively. A larger heterogeneity was obtained 
from soluble tau. Two additional bands of closely related single 
spots slightly decreased in SDS-PAGE mobility and shifted 
towards the acidic end of the NEPHGE gel were observed 
corresponding to each phosphatase-stable and, Since these 
additional bands were sensitive to phosphatase treatment, they 
most likely represent phospho-isoforms of tau, even if the solu- 
ble tau of human brain was demonstrated to be already 
dephosphorylated postmortem [20]. Similar shifts in mobility 
on SDS-PAGE are well-documented for in vitro phos- 
phorylated recombinant tau [21] as well as for the abnor- 
mally high phosphorylated PHF-tau in AD [22-27]. The nega- 
tive charge of the incorporated phosphate residues might de- 
crease the pI of the isoforms, thereby giving rise to the acidic 
shift observed for the phosphatase-sensitive bands in the pres- 
ent study. 
The pattern of dephosphorylated tau resolved on 2D-gels 
was similar, but not identical to the pattern of recombinant tau. 
A pI-microheterogeneity for each molecular tau-isoform still 
remained in the pattern of the dephosphorylated tau as com- 
pared to the recombinant protein. Posttranslational modifica- 
tions other than phosphorylation, such as glycation [28], or 
deamination of several glutamine or asperagine residues are, 
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therefore, likely to contribute to the molecular heterogeneity of 
tau. 
In the normal brain, tau is mainly localised in the axon and 
is thus more abundant in white matter than in grey matter areas 
[29]. In AD and under conditions of other neurodegenerative 
disorders, however, phosphorylated tau-species are also found 
in the somatodendritic compartment [30]. Even in the normal 
brain, tau phospho-isoforms are differentially distributed be- 
tween the axonal and somatodendritic compartment [31]. In 
order to investigate whether similar compartimental differences 
might exist between tau isoforms irrespectively of their phos- 
phorylation state, special attention was paid in the present 
study on a differential distribution of tau isoforms in the white 
matter and grey matter. Major differences were noted with 
respect to the isoforms B and D (designation according to 
Goedert [1]) containing three and four tubulin-binding motifs, 
respectively. The tubulin-binding of tau and the process of 
dynamic stabilisation of microtubuli argely depend on the mo- 
lecular structure of the tubulin-binding domain and their flank- 
ing regions [32]. Tau isoforms with four tubulin-binding motifs 
assemble tubulin in vitro several times faster than three-repeat 
isoforms [33,34]. It was shown, furthermore, that isoform D, 
which was demonstrated to be highly abundant in white matter, 
promotes microtubule-assembly most efficiently [35]. 
While the tau-pool of white matter largely derives from long 
axons of projection neurones, such as pyramidal neurones, 
other compartments, uch as interneurones, and the somato- 
dentritic domain of projection eurones contribute to the tau- 
pool of grey matter. Based on the present results, it might, 
therefore, be hypothesised that axons of projection neurones 
contain about equal amounts of isoforms A, D, B and E, but 
less of isoforms C and F. On the contrary, isoform B, contain- 
ing three tubulin-binding regions, might be the most abundant 
tau isoform of interneurones. This conclusion is supported by 
the previous finding of a differential expression of tau-isoforms 
in long-axon and short-axon eurones. While mRNA for tau 
isoforms containing either three or four tubulin-binding regions 
was detected in pyramidal cells of the cerebral cortex and the 
hippocampal formation, hippocampal granule cells contained 
exclusively mRNA encoding three-repeat isoforms [36]. It re- 
mains to be investigated whether this differential distribution 
of tau-isoforms might causally be related to the high vulnerabil- 
ity of certain long axon projection eurones for 'paired-helical- 
filament' tau in AD. 
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